BC Week In Review | Jan 27, 2014
Clinical News

DEP-Docetaxel: Phase I started

Starpharma began an Australian Phase I trial to evaluate IV DEP-Docetaxel every 3 weeks in about 30 patients with solid tumors. Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) markets Taxotere docetaxel. Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne,...
BC Week In Review | Nov 19, 2012
Clinical News

Starpharma preclinical data

In a mouse model of breast cancer, dendrimer-docetaxel produced concentrations of docetaxel in tumor tissue that were 40 times higher than levels seen with Taxotere docetaxel. The plasma half-life of dendrimer-docetaxel was 60-fold greater than...
Items per page:
1 - 2 of 2